Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients

Cancer Research

Volumn 56, Issue 19, 1996, Pages 4374-4377

  Hemminki, Kari ^a   Rajaniemi, Heli ^a   Lindahl, Bengt ^b   Moberger, Birgitta ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOTIDE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CHROMATOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA ADDUCT; ENDOMETRIUM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; THIN LAYER CHROMATOGRAPHY;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOGENS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA ADDUCTS; DNA DAMAGE; ENDOMETRIUM; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; RATS; SINGLE-BLIND METHOD; TAMOXIFEN;

EID: 0029745072     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Jordan, V G. How safe is tamoxifen? Br. Med. J., 307: 1371-1372, 1992.
2. Greaves, P , Goonettilleke, P , Nunn, G , Topham, J., and Orton, T Two-year carcinogenicity study of tamoxifen in Alderley Rark Wistar-derived rats Cancer Res., 53: 3919-3924, 1993.
3. Hard, G. C., Iatropoulos, M. J , Jordan, K , Radi, L., Kaltenberg, O. P., Imondi, A R., and Williams, G M. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl CD(BR) rats. Cancer Res , 53 4534-4541, 1993.
4. Williams, G M , Iatropoulos, M J , Djordjevics, M. V , and Kaltenberg, O. P. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis (Lond.), 14 315-317, 1993
5. Hirsimaki, P , Hirsimaki, Y., Nieminen, L., and Payne, B. J. Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens. Arch Toxicol , 67: 49-54, 1993.
6. Han, X., and Liehr, J. G Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res., 52: 1360-1363, 1992
7. White, I. N. H., deMatteis, F , Davies, A , Smith, L L , Crofton-Sleigh, C., Venitt, S., Hewer, A., and Phillips, D. H Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells Carcinogenesis (Lond), 13: 2197-2203, 1992.
8. Randerath, K., Bi, J., Mabon, N., Sriram, P., and Moorthy, B. Strong intensification of mouse hepatic tamoxifen DNA adduct formation by pretreatment with the sulfotransferase inhibitor and ubiquitous environmental pollutant pentachlorophenol. Carcinogenesis (Lond.), 15: 797-800, 1994.
9. Osborne M R , Hewer, A , Harcastle, I. R., Carmichael, P. L., and Phillips, D. H. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res , 56: 66-71, 1996.
10. 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis (Lond.), 15: 2087-2094, 1994
11. Hemminki K., Widlak, P., and Hou, S-M. DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis (Lond.), 16: 1661-1664, 1995.
12. Pongracz, K., Pathak, D N., Nakamura, T , Burlingame, A. L , and Bodell, W. J. Activation of the tamoxifen metabolite E to form DNA adducts: comparison with the adducts formed by microsomal activation of tamoxifen. Cancer Res., 55: 3012-3015, 1995.
13. Pathak, D N., and Bodell, W J. DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis (Lond.), 15: 529-532, 1994.
14. Rutqvist, L-E , and Mattson, A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage cancer in a randomized trial of adjuvant tamoxifen. J. Natl. Cancer Inst., 85: 1398-1406, 1993.
15. Fisher, B., Costantino, J. P., Redmond, C. K , Fisher, E. R , Wickerham, D. L., and Cronin W. M Endometrial cancer in tamoxifen-treated breast cancer patient:findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-12 J. Natl. Cancer Inst., 86: 527-537, 1994.
16. King, C. M. Tamoxifen and the induction of cancer. Carcinogenesis (Lond.), 16: 1449-1454, 1995.
17. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol 66. Some Pharmaceutical Drugs Lyon: IARC, 1996.
18. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis (Lond), 16: 1651-1654, 1995.
19. Carmichael, P. L , Ugwumadu, A. H N , Neven, P , Hewer, A J., Poon, G K., and Phillips, D H. Lack of genotoxicity of tamoxifen in human endometrium Cancer Res , 56: 1475-1479, 1996.
20. Phillips, D. H., Hewer, A., Grover, P. L , Poon, G K., and Carmichael, P. L. Tamoxifen does not form detectable adducts in white blood cells of breast cancer patients. Carcinogenesis (Lond), 17: 1149-1152, 1996.
21. 32P-postlabelling techniques. A comparison of HPLC- and TLC-assays. J. Chromatogr , in press. 1996
22. Hemminki, K. DNA adducts, mutations and cancer. Carcinogenesis (Lond), 14: 969-973, 1993.
23. Hemminki, K. DNA adducts in biomonitoring J. Occup Environ. Med , 37: 44-51, 1995.
24. Potter, G A., McCague, R , and Jarman, M A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis (Lond), 15: 439-442, 1994.
25. 5-ethyl)-tamoxifen implicates α-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis (Lond.), 15: 1487-1492, 1994.
26. Försu, A., Staffas, J , and Hemminki, K. Comparison of TLC- and HPLC-32-postlabelling assays for cisplatin-DNA adducts Carcinogenesis (Lond.), 15: 2829-2834, 1994
27. Rothman, N., Bhatnagar, V K , Hayes, R B., Zenser, T. V., Kashyap, S. K., Butler, M A., Bell, D. A., Lakshimi, V , Jaeger, M., Kashyap, R., Hirvonen, A., Schulte, P., Dosemeci, M , Hsu, F, Parikh, D. J , Davis, B. B., and Talaska, G. The impact of interindividual variation m NAT2 activity on benzidine urinary metabolites and urothelial DNA adducts in exposed workers Proc Natl Acad Sci USA, 93: 5084-5089, 1996.